ID | 58764 |
フルテキストURL |
figure.pptx
53.8 KB
|
著者 |
Higo, Hisao
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Taniguchi, Akihiko
Okayama University Hospital
Kaken ID
Senoo, Satoru
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Itano, Junko
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Watanabe, Hiromi
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Oda, Naohiro
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kayatani, Hiroe
National Hospital Organization Okayama Medical Center
Ichikawa, Hirohisa
KKR Takamatsu Hospita
Shibayama, Takuo
National Hospital Organization Okayama Medical Center
Kajimoto, Kazuhiro
Kobe Red Cross Hospital
Kanehiro, Arihiko
Okayama Rosai Hospital
Maeda, Yoshinobu
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kaken ID
researchmap
OKAYAMA respiratory disease study group (ORDSG)
|
抄録 | Background
Pirfenidone suppresses the decline of forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF). However, IPF progresses in some patients despite treatment. We analyzed patients with meaningful FVC declines during pirfenidone treatment and explored the factors predictive of disease progression after FVC decline.
Methods
This study was a retrospective, multicenter, observational study conducted by the Okayama Respiratory Disease Study Group. We defined initial decline in %FVC as 5% or greater per 6-month period during pirfenidone treatment. IPF patients who were treated with pirfenidone and experienced an initial decline from December 2008 to September 2017 were enrolled.
Results
We analyzed 21 patients with IPF. After the initial decline, 4 (19.0%) patients showed improvement in disease, 11 (52.4%) showed stable disease, and 6 (28.6%) showed progressive disease. There was no significant correlation between %FVC reduction on initial decline and subsequent %FVC change (p = 0.475). Deterioration of high-resolution computed tomography (HRCT) findings on initial decline was observed significantly more often in the progressive versus improved/stable disease groups (100% vs 20.0%, p = 0.009).
Conclusions
We revealed that deterioration of HRCT findings may predict disease progression after the initial decline in %FVC in IPF patients treated with pirfenidone.
|
キーワード | Idiopathic pulmonary fibrosis
High-resolution computed tomography
Pirfenidone
Forced vital capacity
|
備考 | This fulltext is available in Feb. 2021.
|
発行日 | 2020-02-23
|
出版物タイトル |
Respiratory Investigation
|
巻 | 58巻
|
号 | 3号
|
出版者 | Elsevier
|
開始ページ | 185
|
終了ページ | 189
|
ISSN | 22125345
|
NCID | AA12579673
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
論文のバージョン | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1016/j.resinv.2019.12.007
|